Academic Department Emergency Medicine, Queen Mary University of London, London, UK.
Barts Health NHS Trust, Leicester, UK.
Emerg Med J. 2018 Aug;35(8):511-515. doi: 10.1136/emermed-2017-207245. Epub 2018 May 28.
Intravenous fluid therapy is one of the most common therapeutic interventions performed in the ED and is a long-established treatment. The potential benefits of fluid therapy were initially described by Dr W B O'Shaughnessy in 1831 and first administered to an elderly woman with cholera by Dr Thomas Latta in 1832, with a marked initial clinical response. However, it was not until the end of the 19th century that medicine had gained understanding of infection risk that practice became safer and that the practice gained acceptance. The majority of fluid research has been performed on patients with critical illness, most commonly sepsis as this accounts for around two-thirds of shocked patients treated in the ED. However, there are few data to guide clinicians on fluid therapy choices in the non-critically unwell, by far our largest patient group. In this paper, we will discuss the best evidence and controversies for fluid therapy in medically ill patients.
静脉输液治疗是急诊科最常见的治疗干预措施之一,也是一种历史悠久的治疗方法。液体治疗的潜在益处最初由 W·B·奥肖内西医生于 1831 年描述,并于 1832 年由托马斯·拉塔医生首次用于一名患有霍乱的老年妇女,最初的临床反应明显。然而,直到 19 世纪末,医学才了解到感染风险,该实践才变得更加安全,并被广泛接受。大多数液体研究都是针对危重病患者进行的,最常见的是败血症,因为这占急诊科治疗的休克患者的三分之二左右。然而,关于非危重病患者液体治疗选择的临床数据很少,而这是我们最大的患者群体。在本文中,我们将讨论医学疾病患者液体治疗的最佳证据和争议。